Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as neutral [1][7]. Core Insights - The pharmaceutical sector experienced a decline of 2.31% on October 15, 2024, outperforming the CSI 300 index by 0.35 percentage points, ranking 19th among 31 sub-industries [5]. - Among sub-industries, blood products (-0.85%), pharmaceutical distribution (-1.19%), and medical consumables (-2.16%) performed relatively well, while medical equipment (-4.00%), vaccines (-3.42%), and medical research outsourcing (-3.10%) lagged [5]. - Notable stock performances included Shuangcheng Pharmaceutical (+9.98%), Duorui Pharmaceutical (+8.96%), and Xiangxue Pharmaceutical (+7.13%), while Haishike (-7.06%), Ruikang Pharmaceutical (-5.48%), and Aibo Medical (-5.45%) saw significant declines [5]. Industry Summary - Recent industry news includes Novartis' application for brolucizumab injection approval in China, which targets VEGF for treating retinal diseases and has shown efficacy internationally [6]. - Company-specific updates include: - Tianyao Pharmaceutical received approval for Lincomycin injection [6]. - Lizhu Group's subsidiary received approval for Leuprolide acetate microspheres [6]. - Haichuang Pharmaceutical received clinical trial approval for HP568 tablets targeting ER+/HER2- advanced breast cancer [6]. - East China Pharmaceutical's subsidiary received approval for HDP-101 clinical trials for BCMA-positive hematological diseases [6].
医药行业周报：诺华布西珠单抗新适应症在华申报上市
Tai Ping Yang·2024-10-16 08:30